JP6778488B2 - 消化酵素抗体およびそれを有する卵と卵を原料とする加工品および抗体を含む組成物と製造方法 - Google Patents
消化酵素抗体およびそれを有する卵と卵を原料とする加工品および抗体を含む組成物と製造方法 Download PDFInfo
- Publication number
- JP6778488B2 JP6778488B2 JP2015551393A JP2015551393A JP6778488B2 JP 6778488 B2 JP6778488 B2 JP 6778488B2 JP 2015551393 A JP2015551393 A JP 2015551393A JP 2015551393 A JP2015551393 A JP 2015551393A JP 6778488 B2 JP6778488 B2 JP 6778488B2
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- ostrich
- lipase
- antibodies
- eggs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L15/00—Egg products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L15/00—Egg products; Preparation or treatment thereof
- A23L15/25—Addition or treatment with microorganisms or enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/06—Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Gynecology & Obstetrics (AREA)
- Zoology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
Description
本発明はまた、以下の項目を提供する。
(項目1)
消化酵素を抗原としてダチョウの雌に接種する工程と、
前記ダチョウの雌が産卵した卵から抗体を精製する工程を含むことを特徴とする消化酵素抗体の製造方法。
(項目2)
前記抗原は、リパーゼ、ラクターゼ、マルターゼ、サッカラーゼ、アミラーゼのうち少なくとも1つを含むことを特徴とする項目1に記載された消化酵素抗体の製造方法。
(項目3)
項目1または2のいずれかの方法で製造された抗体を原料とする組成物であって、前記抗体が消化酵素と結合することを特徴とする組成物。
(項目4)
消化酵素を抗原として鳥類の雌に接種し、前記鳥類の雌が産んだことを特徴とする卵。
(項目5)
前記鳥類がダチョウであることを特徴とする項目1に記載された卵。
(項目6)
項目4または5に記載の前記卵を原料とする加工品。
成熟したメス鳥(ダチョウ、ニワトリ、ウズラ)を用いた。各抗原(リパーゼ、ラクターゼ、マルターゼ、サッカラーゼ、アミラーゼ)50μgをフロイントの完全アジュバント0.2mLと混和し、ダチョウに初回免疫した。各抗原を個別に5羽のダチョウ、5羽のニワトリ、5羽のウズラに接種した。ダチョウもニワトリもウズラも同量の抗原を接種したことになる。
各抗体が消化酵素に対する反応性を以下のようにして調べた。96穴ELISAプレートの各穴に各抗原(リパーゼ、ラクターゼ、マルターゼ、サッカラーゼ、アミラーゼ)10μgを別々に固層化した(室温で4時間)。その後、ダチョウ抗体(各3羽のダチョウから得た卵黄からの抗体の混合物)、ニワトリ抗体(各3羽のニワトリから得た卵黄からの抗体の混合物)、ウズラ抗体(各3羽のウズラから得た卵黄からの抗体の混合物)の段階希釈液(原液は2mg/mL)を各穴に滴下し、室温で1時間反応させた。
<膵リパーゼ活性に及ぼすダチョウ抗体(抗リパーゼ抗体)の阻害作用>
膵リパーゼ活性はトリオレインからのオレイン酸遊離量を測定することによって算出した。トリオレイン80mg(SIGMA)、レシチン10mg(和光純薬工業)、胆汁酸(SIGMA)を9mlの0.1Mトリス緩衝液(pH7.0)中で10分間超音波処理を行うことで均一な懸濁液とし、これを基質液として用いた。
使用したダチョウ卵黄は、リパーゼを免疫したダチョウの卵(初回免疫後8週目)からの卵黄(生)である。ラットを1群6匹として対照群(control)、ダチョウ卵黄投与群(10,100,1000mg/匹)の4群に分け、一晩絶食し、コーンオイル負荷実験を行った。対照群ではコーンオイルエマルジョン1ml及び免疫前卵黄1000mgの混合液を非麻酔科でラットに経口投与した。
使用したダチョウ卵黄は、リパーゼを免疫したダチョウの卵(初回免疫後8週目)からの卵黄(生)を加熱処理(120℃10分)したものである。ラットを1群6匹として対照群(control)、加熱処理ダチョウ卵黄投与群(10,100,1000mg/匹)の4群に分け、一晩絶食し、コーンオイル負荷実験を行った。対照群ではコーンオイルエマルジョン1ml及び免疫前卵黄1000mgの混合液を非麻酔科でラットに経口投与した。
若齢および老齢マウスに高脂肪食およびダチョウ卵黄抗体液(抗リパーゼ抗体)(飲水に添加)を自由摂取させ、経時的に体重を測定した。より具体的に各グループは、若齢マウスで抗リパーゼ抗体を摂取させたグループ(6匹)、若齢マウスで抗リパーゼ抗体を摂取させなかったグループ(6匹)、老齢マウスで抗リパーゼ抗体を摂取させたグループ(6匹)、老齢マウスで抗リパーゼ抗体を摂取させなかったグループ(6匹)である。
Claims (7)
- 肥満の抑制、体重増加の抑制、および/または高脂血症の改善のための経口投与用組成物であって、前記組成物は、消化酵素を抗原としてダチョウを免疫して取得されたダチョウ抗体を含み、前記消化酵素はリパーゼを含む、組成物。
- 前記消化酵素はさらに、ラクターゼ、マルターゼ、サッカラーゼ、および/またはアミラーゼを含む、請求項1に記載の組成物。
- 肥満の抑制のための、請求項1または2に記載の組成物。
- 体重増加の抑制のための、請求項1または2に記載の組成物。
- 高脂血症の改善のための、請求項1または2に記載の組成物。
- 血糖値上昇の抑制のための経口投与用組成物であって、前記組成物は、消化酵素を抗原としてダチョウを免疫して取得されたダチョウ抗体を含み、前記消化酵素はラクターゼ、マルターゼ、サッカラーゼ、およびアミラーゼを含む、組成物。
- 食事と共に摂取されるものであることを特徴とする、請求項1〜6のいずれか1項に記載の組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013249673 | 2013-12-02 | ||
JP2013249673 | 2013-12-02 | ||
JP2014169649 | 2014-08-22 | ||
JP2014169649 | 2014-08-22 | ||
PCT/JP2014/006027 WO2015083374A1 (ja) | 2013-12-02 | 2014-12-02 | 消化酵素抗体およびそれを有する卵と卵を原料とする加工品および抗体を含む組成物と製造方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019146548A Division JP2019199480A (ja) | 2013-12-02 | 2019-08-08 | 消化酵素抗体およびそれを有する卵と卵を原料とする加工品および抗体を含む組成物と製造方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2015083374A1 JPWO2015083374A1 (ja) | 2017-03-16 |
JP6778488B2 true JP6778488B2 (ja) | 2020-11-04 |
Family
ID=53273157
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015551393A Active JP6778488B2 (ja) | 2013-12-02 | 2014-12-02 | 消化酵素抗体およびそれを有する卵と卵を原料とする加工品および抗体を含む組成物と製造方法 |
JP2019146548A Pending JP2019199480A (ja) | 2013-12-02 | 2019-08-08 | 消化酵素抗体およびそれを有する卵と卵を原料とする加工品および抗体を含む組成物と製造方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019146548A Pending JP2019199480A (ja) | 2013-12-02 | 2019-08-08 | 消化酵素抗体およびそれを有する卵と卵を原料とする加工品および抗体を含む組成物と製造方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US10053516B2 (ja) |
JP (2) | JP6778488B2 (ja) |
WO (1) | WO2015083374A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10538593B2 (en) | 2013-12-02 | 2020-01-21 | Ostrich Pharma Kk | Method for manufacturing digestive enzyme antibody and egg having same, and for manufacturing processed product containing egg as ingredient thereof and composition including antibody |
JP6872841B2 (ja) * | 2014-04-28 | 2021-05-19 | アサマ化成株式会社 | 脂肪低減組成物 |
WO2019087372A1 (ja) * | 2017-11-02 | 2019-05-09 | オーストリッチファーマ株式会社 | 細菌感染症用ダチョウ抗体 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3658460B2 (ja) * | 1996-05-27 | 2005-06-08 | 日本製粉株式会社 | 食品、食品の保存方法及び食品保存剤 |
US7344713B1 (en) * | 1997-07-07 | 2008-03-18 | Pimentel Julio L | Decreased fat absorption with an anti-lipase antibody |
DE19748195A1 (de) * | 1997-10-31 | 1999-05-06 | Suedzucker Ag | Disaccharidderivate zur Behandlung von Hyperglykämien |
KR100435829B1 (ko) * | 2001-09-24 | 2004-06-12 | (주)바이오랩 | 수크라아제와 말타아제에 대한 난황항체의 생산방법 및이를 이용한 식이 탄수화물의 흡수 억제용 조성물 |
KR20030079382A (ko) * | 2002-04-04 | 2003-10-10 | 최태부 | 소화 효소-지방산 복합체를 항원으로하여 생산된 항체 및이의 이용 |
CA2521997A1 (en) * | 2003-04-10 | 2004-10-21 | Ghen Corporation | Antiobestic agent using hen's egg antibody against digestive enzymes |
JP4487051B2 (ja) * | 2005-08-29 | 2010-06-23 | 独立行政法人科学技術振興機構 | ダチョウを用いた抗体、及びその作製方法 |
US20110104352A1 (en) | 2008-10-07 | 2011-05-05 | Eco Business Co., Ltd. | Health-Food Product with Mixed-In Concentrated Guava-Leaf Extract of Savoriness Improved by Cereal Grain |
JP2011020927A (ja) * | 2009-07-13 | 2011-02-03 | Ostrich Pharma Kk | ダチョウ産生による抗体およびそれを用いたフィルター |
JP2012211084A (ja) | 2009-07-17 | 2012-11-01 | Amano Enzyme Inc | 酵素組成物 |
JP2012224589A (ja) * | 2011-04-21 | 2012-11-15 | Shuichi Kihata | 糖質吸収抑制物質 |
JP2013147471A (ja) * | 2012-01-23 | 2013-08-01 | Venture Bank Inc | ダチョウ抗体水溶液 |
-
2014
- 2014-12-02 WO PCT/JP2014/006027 patent/WO2015083374A1/ja active Application Filing
- 2014-12-02 US US15/100,821 patent/US10053516B2/en active Active
- 2014-12-02 JP JP2015551393A patent/JP6778488B2/ja active Active
-
2019
- 2019-08-08 JP JP2019146548A patent/JP2019199480A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2015083374A1 (ja) | 2015-06-11 |
US10053516B2 (en) | 2018-08-21 |
JPWO2015083374A1 (ja) | 2017-03-16 |
JP2019199480A (ja) | 2019-11-21 |
US20160304623A1 (en) | 2016-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Al-Khalaifa et al. | Effect of dietary probiotics and prebiotics on the performance of broiler chickens | |
Pan et al. | Effect of selenium-enriched probiotics on laying performance, egg quality, egg selenium content, and egg glutathione peroxidase activity | |
Wang et al. | The gut microbiome-immune axis as a target for nutrition-mediated modulation of food allergy | |
Rangel et al. | Lactose intolerance and cow's milk protein allergy | |
Carrera-Bastos et al. | The western diet and lifestyle and diseases of civilization | |
JP4160132B2 (ja) | ヘリコバクターの阻害 | |
Gujral et al. | Effect of anti-gliadin IgY antibody on epithelial intestinal integrity and inflammatory response induced by gliadin | |
Menge et al. | Effect of cellulose and cholesterol on blood and yolk lipids and reproductive efficiency of the hen | |
JP2008044945A (ja) | 感染症に対抗する代替医薬品としてのプロバイオティクス | |
JP2019199480A (ja) | 消化酵素抗体およびそれを有する卵と卵を原料とする加工品および抗体を含む組成物と製造方法 | |
Zhao et al. | Food chemistry of selenium and controversial roles of selenium in affecting blood cholesterol concentrations | |
US20160287702A1 (en) | Method of Improving Immune Function in Mammals using Lactobacillus Strains with Certain Lipids | |
JP2016029065A (ja) | 腸内環境及び腸管バリア改善組成物 | |
Scott et al. | Soil-transmitted helminths: Does nutrition make a difference? | |
JPWO2003101464A1 (ja) | 抗炎症剤、アレルギー性疾患予防又は改善剤及び機能性食品 | |
JP2011050347A (ja) | α−リノレン酸強化卵及びその用途 | |
US10538593B2 (en) | Method for manufacturing digestive enzyme antibody and egg having same, and for manufacturing processed product containing egg as ingredient thereof and composition including antibody | |
Van Arsdall et al. | Is there a role for the enteral administration of serum-derived immunoglobulins in human gastrointestinal disease and pediatric critical care nutrition? | |
US20060182730A1 (en) | Antiobesity agent using hen's egg antibody against digestive enzymes | |
Rama Rao et al. | Utilization of graded levels of finger millet (Eleusine coracana) in place of yellow maize in commercial broiler chicken diets | |
US20180071237A1 (en) | Treatment method for improving intestinal enviornment and intestinal tract barrier | |
Ben-Nun | THE POTENTIAL BENEFIT OF EGGS | |
WO2008013455A1 (en) | Means and methods for preventing elevated blood glucose levels in humans with animal antibodies produced in milk | |
Plundrich | Protein-polyphenol complexation to reduce food protein allergenicity | |
Arioua et al. | Impacts Of Probiotics On The Production Performance And Immune Status Of Broiler Chickens From Arbor Acre Strains. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160601 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171124 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171124 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181022 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181213 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190513 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190808 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20190808 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20190820 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20190821 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20190913 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20190918 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20200603 |
|
C23 | Notice of termination of proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C23 Effective date: 20200831 |
|
C03 | Trial/appeal decision taken |
Free format text: JAPANESE INTERMEDIATE CODE: C03 Effective date: 20200929 |
|
C30A | Notification sent |
Free format text: JAPANESE INTERMEDIATE CODE: C3012 Effective date: 20200929 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201012 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6778488 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |